Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.

Daemen, Anneleen; Cooper, Jonathan E; Myrta, Szymon; Wongchenko, Matthew J; Lin, Eva; Long, Jason E; Foreman, Oded; Modrusan, Zora; Tremayne, Jarrod R; de la Cruz, Cecile C; Merchant, Mark; Martin, Scott E; Yan, Yibing; Junttila, Melissa R

Daemen, Anneleen; Cooper, Jonathan E; Myrta, Szymon; Wongchenko, Matthew J; Lin, Eva; Long, Jason E; Foreman, Oded; Modrusan, Zora; Tremayne, Jarrod R; de la Cruz, Cecile C; Merchant, Mark; Martin, Scott E; Yan, Yibing; Junttila, Melissa R.

Afiliación

Daemen A; Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, California. anneleen.daemen@oricpharma.com melissa.junttila@oricpharma.com.
Cooper JE; Department of Molecular Oncology, Genentech, Inc., South San Francisco, California.
Myrta S; Roche Global IT Solution Centre, Roche, Warsaw, Poland.
Wongchenko MJ; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Lin E; Department of Molecular Oncology, Genentech, Inc., South San Francisco, California.
Long JE; Department of Molecular Oncology, Genentech, Inc., South San Francisco, California.
Foreman O; Department of Research Pathology, Genentech, Inc., South San Francisco, California.
Modrusan Z; Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, California.
Tremayne JR; Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
de la Cruz CC; Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
Merchant M; Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
Martin SE; Department of Molecular Oncology, Genentech, Inc., South San Francisco, California.
Yan Y; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
Junttila MR; Department of Molecular Oncology, Genentech, Inc., South San Francisco, California. anneleen.daemen@oricpharma.com melissa.junttila@oricpharma.com.

Clin Cancer Res ; 27(4): 1162-1173, 2021 02 15.

Article en En | MEDLINE | ID: mdl-33023953

Asunto(s)

Adenocarcinoma del Pulmón/tratamiento farmacológico; Biomarcadores de Tumor/genética; Neoplasias Pulmonares/tratamiento farmacológico; Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores; Inhibidores de Proteínas Quinasas/uso terapéutico; Adenocarcinoma del Pulmón/diagnóstico; Adenocarcinoma del Pulmón/genética; Adenocarcinoma del Pulmón/patología; Animales; Línea Celular Tumoral; Ensayos Clínicos como Asunto; Conjuntos de Datos como Asunto; Femenino; Heterogeneidad Genética; Humanos; Neoplasias Pulmonares/diagnóstico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patología; Masculino; Ratones; Estadificación de Neoplasias; Inhibidores de Proteínas Quinasas/farmacología; RNA-Seq; Transcriptoma/genética; Ensayos Antitumor por Modelo de Xenoinjerto

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Quinasas de Proteína Quinasa Activadas por Mitógenos / Inhibidores de Proteínas Quinasas / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google